BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-315@pharmaconomics
DTSTAMP:20260707T033826Z
DTSTART;VALUE=DATE:20260702
DTEND;VALUE=DATE:20260703
SUMMARY:RHHBY Phase 3 — divarasib
DESCRIPTION:Phase 3 trial results for divarasib in KRAS G12C non-small cell lung cancer are due Jul 2\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.globenewswire.com/news-release/2026/07/02/3321087/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-s-divarasib-shows-superiority-in-head-to-head-phase-III-trial-against-approved-KRAS-G12C-inhibitors-in-non-small-cell-lung-cancer.html\n\nTrack it: https://pharmaconomics.com/e/315
URL:https://pharmaconomics.com/e/315
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RHHBY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR